Literature DB >> 30396299

MTA1 promotes the invasion and migration of pancreatic cancer cells potentially through the HIF-α/VEGF pathway.

Xianchun Sun1, Yan Zhang2, Bingshu Li2, Haiyan Yang2.   

Abstract

The metastasis-associated gene 1 (MTA1) has previously been recognized as an oncogene, and abnormal MTA1 expression has been related to progression of numerous cancer types to the metastasis stage. However, the function of MTA1 in the regulation of pancreatic cancer progression and metastasis remains unclear. Western blot analysis was adopted to determine the expression of MTA1 in pancreatic cancer tissues and corresponding near normal tissues. Steady clone with MTA1-overexpression and MTA1-inhibitionweregenerated via lentivirus technology in BxPc-3 cells. Transwell assay was carried out for detecting the invasion of pancreatic cancer cells. The migration activity was assessed using the wound scratch assay. The effect of MTA1 in pancreatic cancer was evaluated in the mice xenografts. Western blot analysis was employed to determine the expression of hypoxia inducible factor-α (HIF-α) and vascular endothelial growth factor (VEGF) in vitro and in vivo. We observed that MTA1 overexpression enhanced migration and invasion ability of pancreatic cancer cells in vitro and increased HIF-α and VEGF protein levels in vitro and in vivo. MTA1 inhibition had the opposite effects. MTA1 protein level was positively related to HIF-α and VEGF protein levels. These results indicated that MTA1 potentially promoted pancreatic cancer metastasis via HIF-α/VEGF pathway. This research supplies a new molecular mechanism for MTA1 in the pancreatic cancer progression and metastasis. MTA1 may be an effective therapy target in pancreatic cancer.

Entities:  

Keywords:  HIF-α/VEGF pathway; MTA1; Pancreatic cancer; invasion; migration

Mesh:

Substances:

Year:  2018        PMID: 30396299     DOI: 10.1080/10799893.2018.1531887

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  8 in total

Review 1.  The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.

Authors:  Najah Albadari; Shanshan Deng; Wei Li
Journal:  Expert Opin Drug Discov       Date:  2019-05-09       Impact factor: 6.098

2.  MTA1 Promotes Hepatocellular Carcinoma Progression by Downregulation of DNA-PK-Mediated H1.2T146 Phosphorylation.

Authors:  Yu-Hui Li; Ming Zhong; Hong-Liang Zang; Xiao-Feng Tian
Journal:  Front Oncol       Date:  2020-05-06       Impact factor: 6.244

Review 3.  Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.

Authors:  Tianqi Su; Bo Yang; Tianren Gao; Tongjun Liu; Jiannan Li
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

4.  siMTA1-Loaded Exosomes Enhanced Chemotherapeutic Effect of Gemcitabine in Luminal-b Type Breast Cancer by Inhibition of EMT/HIF-α and Autophagy Pathways.

Authors:  Pengping Li; Guodong Cao; Yuqing Huang; Wei Wu; Bo Chen; Zhenyu Wang; Maoming Xiong
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

5.  High Expression of MTA1 Predicts Unfavorable Survival in Patients With Oral Squamous Cell Carcinoma.

Authors:  Kuan-Yu Lin; Tzu-Cheng Su; Chung-Min Yeh; Wan-Ru Chao; Wen-Wei Sung
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

6.  A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.

Authors:  Akihisa Kato; Serina Ng; Amalraj Thangasamy; Haiyong Han; Wendi Zhou; Stephane Raeppel; Michael Fallon; Sushovan Guha; Sudhakar Ammanamanchi
Journal:  Mol Carcinog       Date:  2021-08-04       Impact factor: 5.139

7.  Novel therapies targeting hypoxia mechanism to treat pancreatic cancer.

Authors:  Wenhao Luo; Jiangdong Qiu; Lianfang Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

8.  Hypoxia-Related Gene FUT11 Promotes Pancreatic Cancer Progression by Maintaining the Stability of PDK1.

Authors:  Wenpeng Cao; Zhirui Zeng; Runsang Pan; Hao Wu; Xiangyan Zhang; Hui Chen; Yingjie Nie; Zijiang Yu; Shan Lei
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.